Recent Advances in Retinal Degeneration pp 107-112 | Cite as
Gene Therapy for Mouse Models of ADRP
Chapter
- 4 Citations
- 1.5k Downloads
Autosomal Dominant Retinitis Pigmentosa (ADRP) is caused by mutations in the rhodopsin gene (RHO) in 30% of patients, and dominant negative mutations are often associated with toxicity of the mutated protein. Preventing or retarding ADRP progression may require the repair or silencing of the defective RHO gene. Two strategies for RHO mRNA silencing have recently been proposed (Millington-Ward et al., 1997; Lewin and Hauswirth, 2001). They are based on the application of therapeutic molecules such as ribozymes (Rz) and small interfering RNA (siRNA) that inhibit RHO expression.
Keywords
Gene Therapy Retinitis Pigmentosa Retinal Degeneration Outer Nuclear Layer Dominant Negative Mutation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- Cashman, S.M., Binkley, E.A., and Kumar-Singh, R., 2005, Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference, Gene Ther., 12: 1223.CrossRefGoogle Scholar
- Gorbatyuk, M.S., Pang, J.J., Thomas, J., Jr., Hauswirth, W.W., and Lewin, A.S., 2005, Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach, Mol. Vis., 11: 648.Google Scholar
- Gorbatyuk, M., Justilien, V., Liu, J., Hauswirth, W.W., and Lewin, A.S., 2007, Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme, Exp. Eye Res., 84: 44.CrossRefGoogle Scholar
- Kiang, A.S., Palfi, A., Ader, M., Kenna, P.F., Millington-Ward, S., Clark,G., Kennan, A., O’Reilly, M., Tam, L.C., Aherne, A., McNally, N., Humphries, P., and Farrar, G.J., 2005, Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach, Mol. Ther., 12: 555.CrossRefGoogle Scholar
- Kijas, J.W., Cideciyan, A.V., Aleman, T.S., Pianta, M.J., Pearce-Kelling, S.E., Miller, B.J., Jacobson, S.G., Aguirre, G.D., and Acland, G.M., 2002, Naturally occurring rhodopsin mutation in the dogcauses retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa, Proc. Natl. Acad. Sci. U.S.A., 99: 6328.CrossRefGoogle Scholar
- LaVail, M.M., Yasumura, D., Matthes, M.T., Drenser, K.A., Flannery, J.G., Lewin, A.S., and Hauswirth, W.W., 2000, Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy, Proc. Natl. Acad. Sci. U.S.A., 97: 11488.PubMedCrossRefGoogle Scholar
- Lewin, A.S. and Hauswirth, W.W., 2001, Ribozyme gene therapy: applications for molecular medicine, Trends Mol. Med., 7: 221.CrossRefGoogle Scholar
- Machida, S., Kondo, M., Jamison, J.A., Khan, N.W., Kononen, L.T., Sugawara, T., Bush, R.A., and Sieving, P.A., 2000, P23H rhodopsin transgenic rat: correlation of retinal function with histopathology, Invest. Ophthalmol. Vis. Sci., 41: 3200.Google Scholar
- Millington-Ward, S., O’Neill, B., Tuohy, G., al Jandal, N., Kiang, A.S., Kenna, P.F., Palfi, A., Hayden, P., Mansergh, F., Kennan, A., Humphries, P., and Farrar, G.J., 1997, Strategems in vitro for gene therapies directed to dominant mutations, Hum. Mol.Genet., 6: 1415.CrossRefGoogle Scholar
- Tessitore, A., Parisi, F., Denti, M.A., Allocca, M., Di Vicino, U., Domenici, L., Bozzoni, I., and Auricchio, A., 2006, Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model, Mol. Ther., 14: 692.CrossRefGoogle Scholar
Copyright information
© Springer Science+Business Media, LLC 2008